OMC
ALXO icon

Oasis Management Company’s ALX Oncology ALXO Stock Holding History

Oasis Management Company’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-106,746
Closed -$1.02M – 112
2022
Q3 		$1.02M Buy
+106,746
New +$1.24M 0.17% 50

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Oasis Management Company's ALXO Position: Q4 2022 in Review

Oasis Management Company sold out of ALX Oncology (ALXO) in Q4 2022, closing a stake of 106,746 shares — an estimated $1.02M sold.

Oasis Management Company first reported a position in ALXO in Q3 2022 and held it in 1 quarter. The position peaked at $1.02M in Q3 2022. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2022.

  • Oasis Management Company reported no remaining ALX Oncology position as of Q4 2022 after selling out during the quarter.
  • Oasis Management Company sold 106,746 ALX Oncology shares in Q4 2022, an estimated $1.02M.
  • Oasis Management Company first reported a position in ALX Oncology in Q3 2022 and held it in 1 quarter.
  • Oasis Management Company's ALX Oncology position peaked at $1.02M in Q3 2022.
  • 87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2022.

Based on Oasis Management Company's 13F filing for Q4 2022, filed 14 Feb 2023.